Navigation Links
Novel therapeutic target identified to decrease triglycerides and increase 'good' cholesterol
Date:10/20/2011

Researchers at NYU Langone Medical Center today announce findings published in the October 20 issue of Nature that show for the first time the inhibition of both microRNA-33a and microRNA-33b (miR-33a/b) with chemically modified anti-miR oligonucleotides markedly suppress triglyceride levels and cause a sustained increase in high density lipoprotein cholesterol (HDL-C) "good" cholesterol.

"The discovery of microRNAs in the last decade has opened new insights for up new avenues for the development of therapies targeted at these potent regulators of gene pathways," said lead author Kathryn Moore, PhD, associate professor in the Department of Medicine, The Leon H. Charney Division of Cardiology and The Marc and Ruti Bell Vascular Biology and Disease Program at NYU Langone Medical Center. "The current study is the first to show that inhibition of miR-33a, as well as miR-33b which is only found in larger mammals can suppress plasma triglyceride levels and increase circulating levels of HDL-C. This study highlights the benefits of modulating miR-33a/b and its downstream metabolic pathways for the treatment of conditions that increase cardiovascular disease risks, such as dyslipidemias and metabolic syndrome."

Metabolic syndrome is a combination of medical disorders that increase the risk of developing cardiovascular disease and diabetes. Cholesterol is a growing public concern worldwide characterized by an increase in triglycerides, decrease in plasma HDL-C, obesity and resistance to insulin that can lead to both cardiovascular disease and diabetes.

Recent studies have indicated miR-33a/b regulate genes involved in cholesterol and fatty acid metabolism pathways. miR-33a/b strongly represses the cholesterol transporter ABCA1, resulting in decreased generation of HDL-C and reverse cholesterol transport. In addition, miR-33a/b also inhibit key genes involved in fatty acid metabolism resulting in the accumulation of triglycerides. The ability to inhibit miR-33a/b to reverse these events provides a novel therapeutic approach to correct dyslipidemia and metabolic syndrome.

"This study represents a significant advance from our proof-of-concept studies in mice showing that anti-miR-33 can both raise HDL and improve existing atherosclerotic vascular disease," said Katey Rayner, PhD in the Department of Medicine at NYU Langone Medical Center and co-author of the study. "These exciting results now bring the use of miR-33 inhibitors one step closer to the clinic."


'/>"/>

Contact: Christopher Rucas
news@nyumc.org
212-404-3753
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. Innovation at Regenstrief: Leveraging novel ideas to improve health care
2. Novel technique reveals both gene number and protein expression simultaneously
3. Novel research set to pinpoint risk of heart attacks and strokes
4. Novel cytokine protects mice from colitis
5. FDA Approves Novel Melanoma Drug
6. St. Michaels North America first to use novel blood-cleaning procedure for kidney transplant
7. Novel DNA sequencer for MDCs systems biology
8. Novel Virus Jumped From Monkeys to Humans, Researchers Find
9. Novel combined therapy extends life, diminishes pain in brain cancer patients
10. Experiment aboard shuttle Atlantis will test novel therapy to build bone during space travel
11. Study uncovers novel genetic variation linked to increased risk of sudden cardiac arrest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... , TwinLink™ - the first dual communication ...
Breaking Medicine Technology: